Last reviewed · How we verify
HIV vaccine 732461
At a glance
| Generic name | HIV vaccine 732461 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Dose-ranging Study to Evaluate the Safety & Immunogenicity of a HIV Vaccine 732461 in Healthy HIV Seronegative Volunteers (PHASE2)
- Evaluation of the Immune Response of a HIV Candidate Vaccine After Administration of One Chloroquine Dose (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HIV vaccine 732461 CI brief — competitive landscape report
- HIV vaccine 732461 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI